HSPT: 15-12G · other
Horizon Space Acquisition II Corp. has filed Form 15-12G to terminate its registration under Section 12(g) and suspend its duty to file reports under Sections 13 and 15(d) of the Securities Exchange Act of 1934. The company is relying on Rules 12g-4(a)(1) and 12h-3(b)(1)(i), which permit the suspension of reporting obligations when the number of holders of record falls below 300. As of the certification date, the company reported approximately one holder of record. This action signals the cessation of the company's public reporting lifecycle and typically precedes the formal delisting or liquidation of the entity.
HSPT: SCHEDULE 13D/A · ownership disclosure
Horizon Space Acquisition II Corp. has filed an amended Schedule 13D disclosing details of its planned business combination with SL BIO Ltd., a Cayman Islands exempted company. The agreement, dated May 9, 2025, establishes a two-step merger process with multiple special purpose entities. The transaction structure involves Merger Sub I merging with Horizon Space Acquisition II Corp., followed by Merger Sub II merging with SL BIO Ltd. The exchange ratio will be based on an enterprise value of $5.568 billion divided by $10.00 per share. SL BIO Ltd. reports having 3,675,000 ordinary shares issued and outstanding as of the agreement date, with a par value of $0.10 per share. Upon completion of the second merger, SL BIO Ltd. will become a wholly-owned subsidiary of the newly formed public company.
HSPT: 25-NSE · delisting
Horizon Space Acquisition II Corp. has filed Form 25-NSE with the SEC, providing voluntary notice of withdrawal from listing and registration on the Nasdaq Stock Market. This filing indicates that the SPAC has failed to complete a business combination within the required timeframe and is proceeding with dissolution and liquidation. Shareholders should expect the ticker to be delisted shortly, with remaining trust assets to be distributed pro rata upon the company's formal winding down.
SL BIO Ltd. and Horizon Space Acquisition II Announce Closing of Business Combination and Listing on the Nasdaq Global Market
SL BIO Ltd. and Horizon Space Acquisition II (HSPT) have officially closed their business combination, creating SL Science Holding Limited. The combined entity will commence trading on the Nasdaq Global Market under the new ticker symbol SLBT on June 15, 2026. The transaction carries an implied equity valuation of approximately $5.568 billion for SL Bio, bolstered by a concurrent $7.8 million PIPE financing to advance its Gamma delta T cell therapies for solid tumors.
HSPT: 10-Q · periodic report
Horizon Space Acquisition II Corp. reported a net loss of $29,122 for the quarter ended March 31, 2026, driven by operating costs of $364,905 and interest expense of $252,293, partially offset by $588,076 in trust interest income. The company has only $9,586 in cash outside its trust account, highlighting severe liquidity constraints. Massive shareholder redemptions occurred during the quarter, with 3,219,311 shares redeemed for $34.2 million, reducing the trust account balance from $72.9 million to $39.4 million. An additional 3.5 million shares remain subject to redemption upon the completion of the proposed business combination with SL Bio, creating a liability of $37.5 million. Management disclosed substantial doubt about the company's ability to continue as a going concern, citing the need for additional financing to complete the business combination or extend the deadline. To address this, the company issued an $850,000 working capital note to its sponsor and a $100,000 note to William Wang, CEO of SL Bio, to fund extension fees and operations.
HSPT: NT 10-Q · late filing
Horizon Space Acquisition II Corp. (HSPT) filed a Form 12b-25 notification on May 15, 2026, stating it is unable to file its quarterly report on Form 10-Q for the period ended March 31, 2026, by the prescribed deadline. The company cites a delay in assembling information and finalizing the report as the primary reason for the late filing. The filing discloses significant operational activity during the quarter, including the deposit of $790,000 in extension fees into the trust account to extend the deadline for consummating its initial business combination. Additionally, the company redeemed 3,219,311 ordinary shares for approximately $34.2 million following shareholder approval of an amendment to its Articles of Association. These redemption and extension activities are expected to cause a significant change in results of operations compared to the prior year period. The inability to file the 10-Q on time, combined with the complexity of these transactions, raises concerns about the company's administrative capacity and potential accounting delays.
HSPT: 8-K · debt financing
Horizon Space Acquisition II Corp. has extended the deadline to consummate its initial business combination by one month to May 18, 2026. This extension is the third of twelve possible one-month extensions permitted under the company's charter amendment. To facilitate the extension, the company's sponsor deposited $50,000 into the trust account. In exchange, the company issued an unsecured promissory note for $50,000 to the sponsor, which bears no interest and is payable upon the earlier of a business combination or the company's liquidation. The sponsor holds the right to convert the note into private units at a price of $10.00 per unit prior to the closing of a business combination. These units consist of one ordinary share and one right to receive one-tenth of one ordinary share.
Horizon Space Acquisition II Corp. Clarifies Redemption Process for Business Combination Shareholder Meeting and Extension Shareholder Meeting
Horizon Space Acquisition II Corp. Postponed the Extraordinary General Meeting to February 12, 2026 and Extended the Redemption Request Deadline
